引用文本：樊启明, 黎人杰, 陈锐建, 等. 加压腹腔气溶胶化疗的若干问题与争议[J/CD]. 消化肿瘤杂志（电子版）, 2025, 17(4): 451-459.

作者：樊启明1， 黎人杰1,2， 陈锐建1，杨梓锋1，李勇1,2

单位：1. 南方医科大学附属广东省人民医院（广东省医学科学院） 胃肠外科，广东 广州 510080；2. 广东省心血管病研究所，广东省人民医院，广东省医学科学院，广东 广州 510080

Authors：Fan Qiming 1, Li Renjie 1,2, Chen Ruijian 1, Yang Zifeng 1, Li Yong1,2

Unit：1. Department of Gastrointestinal Surgery, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Science), Southern Medical University, Guangzhou 510080, Guangdong, China；2. Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong, China

摘要：

加压腹腔气溶胶化疗（pressurized intraperitoneal aerosol chemotherapy, PIPAC）是一种新型的腹腔内局部治疗技术，适用于初诊或复发性腹膜转移癌的治疗。该疗法具有药物分布广泛、组织渗透深入以及摄取效率高等优势。现有证据表明，PIPAC在临床应用中展现出良好的可行性、安全性及耐受性，并有望改善患者的生活质量和预后。国外逾14年的初步临床应用结果显示其具有积极疗效，且已有多部相关共识发布。然而，PIPAC在国内外均仍处于临床研究阶段，全球范围内仍亟需高级别的循证医学证据。鉴于此，本文旨在对PIPAC临床应用中的关键问题与争议进行系统性述评。

关键词：加压腹腔气溶胶化疗；问题；争议

Abstract：

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel locoregional intraperitoneal treatment modality for newly diagnosed or recurrent peritoneal metastasis. This therapy offers advantages such as wide drug distribution, deep tissue penetration, and high uptake efficiency. Clinical evidence supports the favorable feasibility, safety, and tolerability of PIPAC, suggesting its potential to improve patient quality of life and prognosis. Preliminary results from over 14 years of clinical application abroad indicate good efficacy, and multiple relevant consensus guidelines have been published. However, PIPAC remains in the clinical research stage both internationally and domestically, and there is a global imperative for higher-level evidence-based medical evidence. This article aims to provide a systematic review and critical commentary on several issues and controversies regarding the clinical application of PIPAC.

Key words：Pressurized intraperitoneal aerosol chemotherapy; Questions; Controversies

注：网络优先发布